Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Metagenomi (MGX) Equity Average (2023 - 2025)

Metagenomi (MGX) has disclosed Equity Average for 3 consecutive years, with $168.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 31.3% to $168.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $168.5 million, a 31.3% decrease, with the full-year FY2025 number at $196.7 million, up 296.33% from a year prior.
  • Equity Average was $168.5 million for Q4 2025 at Metagenomi, down from $187.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $272.5 million in Q2 2024 to a low of -$96.3 million in Q2 2023.
  • A 3-year average of $129.0 million and a median of $187.1 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 611.59% in 2024, then tumbled 31.3% in 2025.
  • Metagenomi's Equity Average stood at -$67.9 million in 2023, then surged by 461.55% to $245.3 million in 2024, then plummeted by 31.3% to $168.5 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Equity Average are $168.5 million (Q4 2025), $187.1 million (Q3 2025), and $204.2 million (Q2 2025).